Behandlingsfremkaldt NRTI resistens var signifikant mindre hyppigt med fosamprenavir/ ritonavir sammenlignet med nelfinavir (13% mod 57%; p < 0, 001).
Treatment emergent NRTI resistance was significantly less frequent with fosamprenavir/ritonavir compared to nelfinavir (13% versus 57%; p < 0.001).